<DOC>
	<DOCNO>NCT00129142</DOCNO>
	<brief_summary>Androgen deprivation therapy ( ADT ) treatment prostate cancer decrease natural hormone call testosterone . This type therapy effective treatment prostate cancer . However , one side effect bone loss thin bone lead osteoporosis increase risk bone fracture ( break bone ) . The purpose study determine whether addition toremifene citrate ( study drug ) therapy prevent decrease number bone fracture evaluate impact side effect associate testosterone reduction therapy .</brief_summary>
	<brief_title>Toremifene Citrate Prevention Bone Fractures Men With Prostate Cancer Androgen Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>To eligible participation study , subject must meet follow criterion ( minor deviation may discuss medical monitor possible inclusion ) : Give voluntary , sign informed consent accordance institutional policy Be male , age ≥ 50 year Have histologically document prostate cancer . Subjects metastatic prostate cancer may still consider study long disqualify inclusion/exclusion criterion reasonable expectation medical condition interfere objective study adequate followup compliance study protocol achieve full 24month duration study . Have : ADT treatment ( either luteinizing hormonereleasing agonist [ LHRHa ] orchiectomy ) least 6 month ; Or Intermittent LHRHa least precede 12 month acceptable , subject must maintain uninterrupted treatment duration study randomize study . Be age ≥ 70 year BMD lumbar spine femoral neck specify threshold study entry : Hologic BMD ( g/cm2 ) : L1L4 0.926 ; Femoral neck 0.717 Lunar BMD ( g/cm2 ) : L1L4 1.050 ; Femoral neck 0.840 Serum prostatespecific antigen ( PSA ) ≤ 4 ng/mL Have Zubrod performance status ≤ 1 Subject weight &lt; 300 lb ( weight limitation DEXA equipment ) Agree complete daily diary medication intake provide tablet container accurate count Agree use effective method contraception , partner childbearing age , study Have adequate bone marrow , liver renal function : White blood cell ( WBC ) count ≥ 3,000/mm3 ; Platelet count ≥ 100,000/mm3 ; Bilirubin ≤ 1.5 mg/dL ; AST ALT &lt; 2x upper limit normal ; Serum creatinine ≤ 2.0 mg % . Subjects follow eligible enrollment : Taking bisphosphonates , selective estrogen receptor modulators ( SERMs ) , parathyroid hormone ( PTH ) , Forteo® ( teriparatide ) , calcitonin , oral glucocorticoid within 45 day randomization Have disease condition would preclude accurate evaluation radiograph thoracic lumbar spine ( least eight evaluable vertebra range T4 L4 ) [ example , severe scoliosis , sequelae orthopedic procedure surgery ] Have &gt; 4 vertebral fragility fracture Have history carcinoma within last 5 year ( except nonmelanoma cutaneous malignancy superficial bladder cancer evidence recurrence exclude ) . NOTE : Patients cancer nonmelanoma cutaneous malignancy superficial bladder cancer evidence tumor recurrence least 5 year definitive treatment exclude study . Have Paget 's disease bone Have active systemic viral , bacterial fungal infection require treatment Have , judgment investigator , clinically significant concurrent illness psychological , familial , sociological , geographical concomitant condition would permit adequate followup compliance study protocol full 24month duration study Received treatment investigational agent within 30 day prior randomization Taking finasteride ( e.g. , Proscar® ) , dutasteride ( e.g. , Avodart® ) , Danocrine® ( danazol ) testosteronelike supplement , dehydroepiandrosterone ( DHEA ) [ subject eligible stop agent total washout 45 day prior randomization agree use agent duration study ] Taking herbal medicine dietary supplement prostate health , PC SPES saw palmetto ( also know Serenoa repens ) [ subject eligible stop agent total washout 45 day prior randomization agree use agent duration study ] . Lycopene selenium prohibit washout require . Have history thromboembolic disease include deep vein thrombosis pulmonary embolus Have history chronic hepatitis cirrhosis Have receive prior treatment toremifene</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Fractures</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
</DOC>